These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 21742513)

  • 1. Autocrine production of interleukin-8 confers cisplatin and paclitaxel resistance in ovarian cancer cells.
    Wang Y; Qu Y; Niu XL; Sun WJ; Zhang XL; Li LZ
    Cytokine; 2011 Nov; 56(2):365-75. PubMed ID: 21742513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells.
    Wang Y; Niu XL; Qu Y; Wu J; Zhu YQ; Sun WJ; Li LZ
    Cancer Lett; 2010 Sep; 295(1):110-23. PubMed ID: 20236757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Chemotherapy resistance induced by interleukin-6 in ovarian cancer cells and its signal transduction pathways].
    Wang Y; Li LZ; Ye L; Niu XL; Liu X; Zhu YQ; Sun WJ; Liang YJ
    Zhonghua Fu Chan Ke Za Zhi; 2010 Sep; 45(9):691-8. PubMed ID: 21092551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. XIAP gene downregulation by small interfering RNA inhibits proliferation, induces apoptosis, and reverses the cisplatin resistance of ovarian carcinoma.
    Ma JJ; Chen BL; Xin XY
    Eur J Obstet Gynecol Reprod Biol; 2009 Oct; 146(2):222-6. PubMed ID: 19758744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-6 signaling regulates anchorage-independent growth, proliferation, adhesion and invasion in human ovarian cancer cells.
    Wang Y; Li L; Guo X; Jin X; Sun W; Zhang X; Xu RC
    Cytokine; 2012 Aug; 59(2):228-36. PubMed ID: 22595649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
    Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
    Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of HtrA2/Omi by X-linked inhibitor of apoptosis protein in chemoresistance in human ovarian cancer cells.
    Yang X; Xing H; Gao Q; Chen G; Lu Y; Wang S; Ma D
    Gynecol Oncol; 2005 May; 97(2):413-21. PubMed ID: 15863139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cisplatin-induced apoptosis proceeds by caspase-3-dependent and -independent pathways in cisplatin-resistant and -sensitive human ovarian cancer cell lines.
    Henkels KM; Turchi JJ
    Cancer Res; 1999 Jul; 59(13):3077-83. PubMed ID: 10397248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bcl-xL is expressed in ovarian carcinoma and modulates chemotherapy-induced apoptosis.
    Liu JR; Fletcher B; Page C; Hu C; Nunez G; Baker V
    Gynecol Oncol; 1998 Sep; 70(3):398-403. PubMed ID: 9790794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BCL-2 family protein expression and platinum drug resistance in ovarian carcinoma.
    Beale PJ; Rogers P; Boxall F; Sharp SY; Kelland LR
    Br J Cancer; 2000 Jan; 82(2):436-40. PubMed ID: 10646901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic protein 1 in the paclitaxel-resistant phenotype.
    Duan Z; Feller AJ; Penson RT; Chabner BA; Seiden MV
    Clin Cancer Res; 1999 Nov; 5(11):3445-53. PubMed ID: 10589757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Study of bcl-2 antisense oligodeoxynucleotides on reversal of cisplatin resistance in ovarian cancer cell line A2780/DDP].
    Li M; Yu LL; Cai LQ; Wang HB; Wang ZH; Wang ZH
    Zhonghua Fu Chan Ke Za Zhi; 2006 Feb; 41(2):121-5. PubMed ID: 16640863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-8 secretion by ovarian cancer cells increases anchorage-independent growth, proliferation, angiogenic potential, adhesion and invasion.
    Wang Y; Xu RC; Zhang XL; Niu XL; Qu Y; Li LZ; Meng XY
    Cytokine; 2012 Jul; 59(1):145-55. PubMed ID: 22579115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Role of apoptosis-associated genes and caspase-3 in cisplatin-resistant human ovarian cancer cell lines].
    Yang XK; Xing H; Zheng F; Gao QL; Wang W; Lu YP; Ma D
    Zhonghua Fu Chan Ke Za Zhi; 2003 Mar; 38(3):158-61. PubMed ID: 12816691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
    Judson PL; Watson JM; Gehrig PA; Fowler WC; Haskill JS
    Cancer Res; 1999 May; 59(10):2425-32. PubMed ID: 10344753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absence of Bcl-xL down-regulation in response to cisplatin is associated with chemoresistance in ovarian carcinoma cells.
    Villedieu M; Louis MH; Dutoit S; Brotin E; Lincet H; Duigou F; Staedel C; Gauduchon P; Poulain L
    Gynecol Oncol; 2007 Apr; 105(1):31-44. PubMed ID: 17275076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of cell death events induced by anti-neoplastic drugs cisplatin, paclitaxel and 5-fluorouracil on human hepatoma cell lines: Possible mechanisms of cell resistance.
    Brenes O; Arce F; Gätjens-Boniche O; Díaz C
    Biomed Pharmacother; 2007 Jul; 61(6):347-55. PubMed ID: 17399942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of p53 and drug resistance following treatment with cisplatin or paclitaxel in ovarian cancer cell lines.
    Metzinger DS; Taylor DD; Gercel-Taylor C
    Cancer Lett; 2006 May; 236(2):302-8. PubMed ID: 15990222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tanshinone IIA acts via p38 MAPK to induce apoptosis and the down-regulation of ERCC1 and lung-resistance protein in cisplatin-resistant ovarian cancer cells.
    Jiao JW; Wen F
    Oncol Rep; 2011 Mar; 25(3):781-8. PubMed ID: 21165580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thyroid cancer resistance to chemotherapeutic drugs via autocrine production of interleukin-4 and interleukin-10.
    Stassi G; Todaro M; Zerilli M; Ricci-Vitiani L; Di Liberto D; Patti M; Florena A; Di Gaudio F; Di Gesù G; De Maria R
    Cancer Res; 2003 Oct; 63(20):6784-90. PubMed ID: 14583474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.